Please join Xilio Therapeutics for a virtual program spotlight on XTX301: A Tumor-Activated IL-12, featuring key opinion leader (KOL) Diwakar Davar, MBBS, M.Sc (UPMC Hillman Cancer Center), who will discuss the unmet medical need in treating patients with “cold” advanced solid tumors. Dr. Davar will discuss the differences between “cold” and “hot” tumors in the tumor microenvironment (TME), as well as the potential for IL-12 as a compelling immunotherapy target across tumor types due to its ability to activate both the innate and adaptive immune system.

René Russo, Chief Executive Officer, Marty Huber, President and Head of R&D and Uli Bialucha, Chief Scientific Officer of Xilio will discuss the company’s clinical-stage molecule, XTX301, a unique tumor-activated, engineered IL-12 designed to potently stimulate anti-tumor immunity and reprogram the TME of poorly immunogenic “cold” tumors towards an inflamed (or “hot”) state, while limiting systemic toxicity.  The Xilio team will also cover the adaptive design for the planned Phase 1 trial for XTX301 and anticipated clinical development timeline.